u/No-Anteater5184

The author owns ADTX and argues the definitive business combination valuing Ignite Proteomics at about $150 million, with Ignite expected to become a separate publicly traded company while ADTX remains public, makes the story more interesting than most realize. He notes a simple math exercise using approximately 997.9 million shares outstanding implies about $0.15 per share of Ignite value, though he explicitly says this is not a prediction or price target. The catalyst is successful closing of the deal and management execution; stated risks include unmet closing conditions, financing/regulatory approvals, dilution from convertible notes, and micro-cap biotech volatility.